3 years ago

Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Mark Lunt, Kayleigh J Mason, Kathleen McElhone, Ireny Y K Iskandar, Darren M Ashcroft, Christopher E M Griffiths, Nick J Reynolds, Richard B Warren, Catherine H Smith, Ian Evans
Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse events (AEs) or ineffectiveness in psoriasis patients who had failed a first biologic and switched to a second in a large, multi-centre pharmacovigilance registry (n=1239; adalimumab,538; etanercept,104; ustekinumab,597). The overall drug survival rate in the first year after switching was 77% (95% confidence interval (CI): 74%-79%), falling to 58% (55%-61%) in the third year. Female gender, multiple comorbidities, concomitant therapy with ciclosporin, and a high Psoriasis Area and Severity Index at switching onto the second-line biologic were predictors of overall discontinuation (multivariable Cox proportional hazard model). Compared to adalimumab, patients receiving etanercept were more likely to discontinue therapy (hazard ratio 1.95; 95% CI:1.46-2.59), whereas patients on ustekinumab were more likely to persist (0.46;0.37-0.58). Discontinuation of the first biologic due to AEs was associated with an increased rate of second drug discontinuation due to AEs (2.48;1.48-4.16). In conclusion, drug survival rates differed amongst biologics and decreased over time; second-line discontinuation due to AEs was more common among those who discontinued first-line treatment for this reason. The results of this study should support clinical decision making when choosing second-line biologic therapy for patients with psoriasis.

Publisher URL: http://doi.org/10.1016/j.jid.2017.09.044

DOI: 10.1016/j.jid.2017.09.044

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.